Omega Diagnostics Share Price Gains on Partnership with DAM Health

Trade Omega Diagnostics Shares Your Capital Is At Risk
Sam Boughedda
Updated: 1 Nov 2021

On Monday, Omega Diagnostics (LON: ODX) shareholders received a boost with the company saying it has signed a Head of Terms partnership agreement with DAM Health Limited a mobile Covid-19 test provider.


The agreement will see Omega exclusively supply its VISITECT professional use COVID-19 Antigen tests to DAM Health's testing clinics throughout the UK and Europe. 

Also Read: Omega Diagnostics Stock Price Forecast

Omega has already received an initial purchase order of over £750,000 to supply VISITECT professional use COVID-19 antigen tests to DAM Health.

The partnership is for an initial period of 12-months. With the initial agreement focused around the VISITECT professional Antigen LFTs, Omega said it is possible to broaden the partnership to include its VISITECT antigen self-test LFT — once it is approved — and for DAM Health to sell Omega's Food Detective product throughout its network. 

There is also an outline to extend the partnership beyond Europe, as DAM Health expand their international network of clinics globally.

Colin King, CEO of Omega Diagnostics, said: “We are delighted to be to be utilising some of our lateral flow test production capacity and to be working with DAM Health, who are leaders in the space.

“Reaching a commercial agreement with a leading and fast-growing testing provider is a major milestone for the company in bringing our gold-standard test to market and we look forward to working collaboratively with DAM Health and are hopeful that this partnership can be broadened to cover more of Omega's products, not just in the COVID space.”

Omega's share price is up 7% at 53p so far Monday morning.

Should you invest in Omega Diagnostics shares?

Omega Diagnostics shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are ODX shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .